PCS was tasked by UNIDO to audit the Zimbabwean pharmaceutical industry based on 17 key GMP elements defined in the WHO's Technical Report Series (TRS). Zimbabwe's pharmaceutical sector plays a crucial role in the country's healthcare system. However, it faces challenges related to infrastructure, regulatory compliance, and adherence to international quality standards. Despite these challenges, the industry has shown potential for growth and development. In recent years, the Zimbabwean government, in collaboration with international organizations like UNIDO, has been working to upgrade the GMP standards of its pharmaceutical industry. This intervention aims to enhance the quality and safety of pharmaceutical products manufactured in Zimbabwe, thereby improving public health outcomes and bolstering the industry's competitiveness in the global market. The UNIDO intervention is part of broader efforts to strengthen the capacity of developing countries to meet international quality standards and regulatory requirements. By supporting the Zimbabwean pharmaceutical industry in improving its GMP practices, UNIDO seeks to enhance the industry's reputation, increase export opportunities, and attract investment. Through rigorous audits and consultations, PCS assists UNIDO in evaluating the compliance of Zimbabwean pharmaceutical companies with international GMP standards. This collaboration contributes to building trust in Zimbabwean pharmaceutical products and promoting sustainable development in the country's healthcare sector. PCS was tasked by UNIDO to audit the Zimbabwean pharmaceutical industry based on 17 key GMP elements defined in the WHO's Technical Report Series (TRS).
